Literature DB >> 12188923

Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors.

Valérie Antonio1, Arthur Brouillet, Brigitte Janvier, Claire Monne, Gilbert Bereziat, Marise Andreani, Michel Raymondjean.   

Abstract

The abundant secretion of type IIA secreted phospholipase A(2) (sPLA(2)) is a major feature of the inflammatory process of atherosclerosis. sPLA(2) is crucial for the development of inflammation, as it catalyses the production of lipid mediators and induces the proliferation of smooth muscle cells. We have analysed the activation of sPLA(2) transcription by cAMP and interleukin-1beta (IL-1beta), and shown that the 500 bp region upstream of the transcription start site of the rat sPLA(2) gene is implicated in activation by synergistically acting cAMP and IL-1beta. We transiently transfected and stimulated rat smooth muscle cells in primary culture and measured the promoter activities of serial and site-directed deletion mutants of sPLA(2)-luciferase constructs. A distal region, between -488 and -157 bp, bearing a CAAT/enhancer binding protein (C/EBP)-responsive element (-242 to -223) was sufficient for cAMP/protein kinase A-mediated sPLA(2) promoter activation. We find evidence for the first time that activation of the sPLA(2) promoter by IL-1beta requires activation of an Ets-responsive element in the -184 to -180 region of the distal promoter via the Ras pathway and a nuclear factor-kappaB site at positions -141 to -131 of the proximal promoter. We also used electrophoretic mobility shift assays to identify five binding sites for the Sp1 factor; a specific inhibitor of Sp1, mithramycin A, showed that this factor is crucial for the basal activity of the sPLA(2) promoter.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12188923      PMCID: PMC1223003          DOI: 10.1042/BJ20020658

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

Review 1.  The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation.

Authors:  M Karin
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

2.  Chimeric smooth muscle-specific enhancer/promoters: valuable tools for adenovirus-mediated cardiovascular gene therapy.

Authors:  S Ribault; P Neuville; A Méchine-Neuville; F Augé; A Parlakian; G Gabbiani; D Paulin; V Calenda
Journal:  Circ Res       Date:  2001-03-16       Impact factor: 17.367

3.  Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB.

Authors:  S Hoshi; M Goto; N Koyama; K Nomoto; H Tanaka
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

4.  TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2.

Authors:  S Goetze; U Kintscher; K Kaneshiro; W P Meehan; A Collins; E Fleck; W A Hsueh; R E Law
Journal:  Atherosclerosis       Date:  2001-11       Impact factor: 5.162

5.  Induction of secreted type IIA phospholipase A2 gene transcription by interleukin-1beta. Role of C/EBP factors.

Authors:  C Massaad; M Paradon; C Jacques; C Salvat; G Bereziat; F Berenbaum; J L Olivier
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

6.  Sp1 and ETS family transcription factors regulate the mouse Mta2 gene expression.

Authors:  L Xia; Y Zhang
Journal:  Gene       Date:  2001-05-02       Impact factor: 3.688

Review 7.  Phospholipase A(2) in vascular disease.

Authors:  E Hurt-Camejo; G Camejo; H Peilot; K Oörni; P Kovanen
Journal:  Circ Res       Date:  2001-08-17       Impact factor: 17.367

8.  Protein kinase A-dependent stimulation of rat type II secreted phospholipase A(2) gene transcription involves C/EBP-beta and -delta in vascular smooth muscle cells.

Authors:  C Couturier; V Antonio; A Brouillet; G Béréziat; M Raymondjean; M Andréani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

9.  Secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2 in murine bone marrow-derived mast cells.

Authors:  A N Fonteh; G Atsumi; T LaPorte; F H Chilton
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

10.  Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid.

Authors:  J J Seilhamer; W Pruzanski; P Vadas; S Plant; J A Miller; J Kloss; L K Johnson
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

View more
  21 in total

1.  Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.

Authors:  Leslie Oleksowicz; Yin Liu; R Bruce Bracken; Krishnanath Gaitonde; Barbara Burke; Paul Succop; Linda Levin; Zhongyun Dong; Shan Lu
Journal:  Prostate       Date:  2011-11-29       Impact factor: 4.104

2.  Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites.

Authors:  Mireille Basselin; Epolia Ramadan; Mei Chen; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2010-10-28       Impact factor: 3.996

3.  Trafficking of endogenous smooth muscle cell cholesterol: a role for serum amyloid A and interleukin-1β.

Authors:  Lawrence G Pessolano; Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Laura Liscum; Phillip J Stone; Jean D Sipe; Barbara M Schreiber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

4.  Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.

Authors:  Pragya Sharma; Shalini Thakran; Xiong Deng; Marshall B Elam; Edwards A Park
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

5.  Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.

Authors:  Zhongyun Dong; Yin Liu; Kieran F Scott; Linda Levin; Krishnanath Gaitonde; R Bruce Bracken; Barbara Burke; Qihui Jim Zhai; Jiang Wang; Leslie Oleksowicz; Shan Lu
Journal:  Carcinogenesis       Date:  2010-09-13       Impact factor: 4.944

6.  Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA).

Authors:  Fan Zhang; Jian Sha; Thomas G Wood; Cristi L Galindo; Harold R Garner; Mark F Burkart; Giovanni Suarez; Johanna C Sierra; Stacy L Agar; Johnny W Peterson; Ashok K Chopra
Journal:  Cell Signal       Date:  2008-01-17       Impact factor: 4.315

7.  Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory phospholipase A2 gene in rat smooth-muscle cells.

Authors:  Valérie Antonio; Brigitte Janvier; Arthur Brouillet; Marise Andreani; Michel Raymondjean
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

8.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

9.  Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6.

Authors:  Lucas Ravaux; Chantal Denoyelle; Claire Monne; Isabelle Limon; Michel Raymondjean; Khadija El Hadri
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

10.  Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism.

Authors:  Michael S Kuefner; Kevin Pham; Jeanna R Redd; Erin J Stephenson; Innocence Harvey; Xiong Deng; Dave Bridges; Eric Boilard; Marshall B Elam; Edwards A Park
Journal:  J Lipid Res       Date:  2017-06-29       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.